AI FOR PRECISION ONCOLOGY
unsplash-image-UpKCxjVM8wU.jpg

Precision Oncology Powered by AI and Omics

Arcas provides a cost-efficient and more precise drug discovery and diagnostics pipeline for oncology

Arcas is a precision oncology therapeutics platform built around state-of-the-art AI technology. We are using a multi-level deep learning approach to integrate clinical, genomic, and pharmacological data.

Arcas allows us to leverage complex molecular signatures and make use of pre-clinical drug screening data in a way that is predictive of clinical performance. This technology offers unmatched translatability of pre-clinical drug screening information. In a similar vein, Arcas technology enables more precise biomarkers for future clinical trials which will turn into more precise companion diagnostics.

Arcas precision oncology platform is financially and organizationally supported by the Berlin Institute of Health and Max Delbrück Center for Molecular Medicine.

 

What are we looking for?

We are looking for industry partners to deploy our AI-augmented drug screens in drug development process.

In addition, we are looking for national and international cooperation with clinicians and clinics on cancer drug trials.

 

Partner and unleash the potential of clinical data!

 
844.jpg
 

OUR TEAM

 
 

Advisors

 
BUMSB_small.png

Prof. Nikolaus Rajewsky (Genomics)

a2a.png

Dr. Elena Diez (Business Dev)

charite.png

Prof. David Capper (Pathologist)
Prof. Angelika Eggert (Oncologist)

WCM.png

Prof. Chris Mason (Genomics)